---
title: Acute resistance to BET inhibitors remodels compensatory transcriptional programs
  via p300 coactivation
date: '2024-12-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39651888/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241210175340&v=2.18.0.post9+e462414
source: Blood
description: Initial clinical trials with drugs targeting epigenetic modulators -
  such as bromodomain and extraterminal protein (BET) inhibitors - demonstrate modest
  results in acute myeloid leukemia (AML). A major reason for this involves an increased
  transcriptional plasticity within AML, which allows cells to escape the therapeutic
  pressure. In this study, we investigated immediate epigenetic and transcriptional
  responses following BET inhibition and could demonstrate that BET inhibitor-mediated
  ...
disable_comments: true
---
Initial clinical trials with drugs targeting epigenetic modulators - such as bromodomain and extraterminal protein (BET) inhibitors - demonstrate modest results in acute myeloid leukemia (AML). A major reason for this involves an increased transcriptional plasticity within AML, which allows cells to escape the therapeutic pressure. In this study, we investigated immediate epigenetic and transcriptional responses following BET inhibition and could demonstrate that BET inhibitor-mediated ...